576 related articles for article (PubMed ID: 19625715)
1. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan.
Khan MI; Soofi SB; Ochiai RL; Habib MA; Sahito SM; Nizami SQ; Acosta CJ; Clemens JD; Bhutta ZA;
Vaccine; 2012 Aug; 30(36):5389-95. PubMed ID: 22721899
[TBL] [Abstract][Full Text] [Related]
3. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyphâ„¢) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
6. Population impact of Vi capsular polysaccharide vaccine.
Khan MI; Ochiai RL; Clemens JD
Expert Rev Vaccines; 2010 May; 9(5):485-96. PubMed ID: 20450323
[TBL] [Abstract][Full Text] [Related]
7. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design.
Acosta CJ; Galindo CM; Ali M; Elyazeed RA; Ochiai RL; Danovaro-Holliday MC; Page AL; Thiem VD; Jin Y; Park JK; Lee H; Puri MK; Ivanoff B; Agtini MD; Soeharno R; Simanjuntak CH; Punjabi NH; Canh DG; Sur D; Nizami Q; Manna B; Bai-qing D; Anh DD; Honghui Y; Bhattacharya SK; Bhutta Z; Trach DD; Xu ZY; Pang T; Donner A; Clemens JD
Trop Med Int Health; 2005 Dec; 10(12):1219-28. PubMed ID: 16359401
[TBL] [Abstract][Full Text] [Related]
8. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.
Yang HH; Kilgore PE; Yang LH; Park JK; Pan YF; Kim Y; Lee YJ; Xu ZY; Clemens JD
J Infect Dis; 2001 Jun; 183(12):1775-80. PubMed ID: 11372030
[TBL] [Abstract][Full Text] [Related]
9. Impact of Vi vaccination on spatial patterns of typhoid fever in the slums of Kolkata, India.
Ali M; Sur D; Kim DR; Kanungo S; Bhattacharya SK; Manna B; Ochiai RL; Clemens J
Vaccine; 2011 Nov; 29(48):9051-6. PubMed ID: 21939716
[TBL] [Abstract][Full Text] [Related]
10. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
[TBL] [Abstract][Full Text] [Related]
11. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
Yang HH; Wu CG; Xie GZ; Gu QW; Wang BR; Wang LY; Wang HF; Ding ZS; Yang Y; Tan WS; Wang WY; Wang XC; Qin M; Wang JH; Tang HA; Jiang XM; Li YH; Wang ML; Zhang SL; Li GL
Bull World Health Organ; 2001; 79(7):625-31. PubMed ID: 11477965
[TBL] [Abstract][Full Text] [Related]
12. Safety of Typhim Vi vaccine in a postmarketing observational study.
Marcus LC; Froeschle JE; Hill DR; Wolfe MS; Maus D; Connor B; Acosta AM; Rensimer ER; Roberts A; Dardick K
J Travel Med; 2007; 14(6):386-91. PubMed ID: 17995534
[TBL] [Abstract][Full Text] [Related]
13. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
[No Abstract] [Full Text] [Related]
14. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
Arya SC; Agarwal N
N Engl J Med; 2009 Nov; 361(22):2191; author reply 2192-3. PubMed ID: 19940305
[No Abstract] [Full Text] [Related]
15. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.
Mirza NB; Wamola IA; Estambale BA; Mbithi E; Poillet M
East Afr Med J; 1995 Mar; 72(3):162-4. PubMed ID: 7796767
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for preventing typhoid fever.
Milligan R; Paul M; Richardson M; Neuberger A
Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
18. A Salmonella typhi Vi conjugate vaccine.
Koul PA
N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
[No Abstract] [Full Text] [Related]
19. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea.
Lim SM; Jung HS; Kim MJ; Park DW; Kim WJ; Cheong HJ; Park SC; Lee KC; Shin YK; Tan HK; Kim SL; Sohn JW
J Microbiol Biotechnol; 2007 Apr; 17(4):611-5. PubMed ID: 18051272
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]